Helen Susan Kim - 08 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)

Role
Director, 10%+ Owner
Signature
/s/ Helen Susan Kim
Issuer symbol
AKTS
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
3
Filing time
08 Jan 2026, 21:09:21 UTC
Previous filing
16 May 2025
Next filing
12 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kim Helen Susan Director, 10%+ Owner C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON /s/ Helen Susan Kim 08 Jan 2026 0001422772

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTS Series A Redeemable Convertible Preferred Stock 08 Jan 2026 Common Stock 3,900,284 See Footnote F1, F2
holding AKTS Series A Redeemable Convertible Preferred Stock 08 Jan 2026 Common Stock 108,229 See Footnote F1, F3
holding AKTS Series B Redeemable Convertible Preferred Stock 08 Jan 2026 Common Stock 959,086 See Footnote F2, F4
holding AKTS Series B Redeemable Convertible Preferred Stock 08 Jan 2026 Common Stock 26,613 See Footnote F3, F4
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 37,866 $18.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and has no expiration date. All shares of Series A Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
F2 These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
F3 These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
F4 Each share of Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and has no expiration date. All shares of Series B Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
F5 1/36th of the original number of shares subject to the option shall vest in monthly installments from January 8, 2026, subject to the Reporting Person's continuous service to the Issuer on and through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney